Hormone Sensitive Advanced Prostate Cancer Market
- As per DelveInsight, the Hormone Sensitive Advanced Prostate Cancer Market is expected to expand at a healthy growth rate during the forecast period (2023-2032), owing to the launch of new therapies in the market and the rise in the number of cases.
- Limited number of pharma and biotech companies are actively working in the Hormone Sensitive Advanced Prostate Cancer market. However, the pipeline therapies hold the potential to significantly improve the treatment outlook.
Download the Sample PDF to Get More Insight @ Hormone Sensitive Advanced Prostate Cancer Market
DelveInsight's "Hormone Sensitive Advanced Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hormone Sensitive Advanced Prostate Cancer, historical and forecasted epidemiology as well as the Hormone Sensitive Advanced Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hormone Sensitive Advanced Prostate Cancer market report provides current treatment practices, emerging drugs, Hormone Sensitive Advanced Prostate Cancer Market share of the individual therapies, current and forecasted Hormone Sensitive Advanced Prostate Cancer market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hormone Sensitive Advanced Prostate Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hormone Sensitive Advanced Prostate Cancer market.
Hormone Sensitive Advanced Prostate Cancer Disease Understanding and Treatment Algorithm
Hormone Sensitive Advanced Prostate Cancer, often referred to as hormone-sensitive prostate cancer (HSPC), is a stage of prostate cancer where cancer cells still respond to hormonal therapies. This means that the growth and progression of the cancer are driven by male hormones, primarily testosterone. Treatment options for HSPC often include hormonal therapies aimed at reducing the levels of these hormones in the body.
Get More Insights of this Report @ Prostate Cancer Treatment Market Size
Causes and Risk Factors of Hormone Sensitive Advanced Prostate Cancer
The exact cause of prostate cancer is not fully understood, but there are several known risk factors:
- Age: The risk of developing prostate cancer increases with age, and it is more common in older men.
- Family History: A family history of prostate cancer, especially in first-degree relatives, can increase an individual's risk.
- Race and Ethnicity: African American men have a higher risk of developing prostate cancer and are more likely to develop aggressive forms of the disease.
- Genetics: Certain genetic mutations and variants may increase the risk of prostate cancer.
- Diet and Lifestyle: A diet high in red meat and dairy products and low in fruits and vegetables may contribute to an increased risk of prostate cancer.
- Hormonal Factors: Hormonal imbalances, such as high levels of testosterone, can influence the development and progression of prostate cancer.
Hormone Sensitive Advanced Prostate Cancer Signs and Symptoms
The symptoms of Hormone Sensitive Advanced Prostate Cancer are often similar to those of early-stage prostate cancer, and they may include:
- Frequent urination, especially at night
- Difficulty starting or maintaining a urine stream
- Weak urine flow
- Blood in the urine or semen.
- Pain or discomfort in the pelvic area
- Erectile dysfunction
- Bone pain, indicating potential metastasis to the bones
It's important to note that some individuals with HSPC may not experience noticeable symptoms, which highlights the importance of regular screening for prostate cancer, particularly in those at higher risk.
Hormone Sensitive Advanced Prostate Cancer Diagnosis
Diagnosing HSPC involves a series of tests and evaluations to confirm the presence and extent of the cancer:
- Digital Rectal Examination (DRE): A physical examination in which a healthcare provider checks the prostate for abnormalities through the rectum.
- Prostate-Specific Antigen (PSA) Test: A blood test that measures the levels of PSA, a protein produced by the prostate. Elevated PSA levels can be an indicator of prostate cancer.
- Biopsy: If the PSA test and DRE suggest the presence of cancer, a biopsy is performed to collect tissue samples from the prostate. These samples are then analyzed under a microscope to confirm the diagnosis and determine the cancer's grade and stage.
- Imaging: Imaging tests such as ultrasound, MRI, and CT scans may be used to assess the extent of the cancer, including whether it has spread beyond the prostate.
Hormone Sensitive Advanced Prostate Cancer Treatment Scenario
The treatment of HSPC primarily revolves around hormonal therapy, also known as androgen deprivation therapy (ADT). This treatment aims to reduce the levels of male hormones, particularly testosterone, in the body, as these hormones fuel the growth of prostate cancer cells.
In some cases, treatment for HSPC may include:
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonists: These medications lower testosterone production by the testes and are administered through injections or implants.
- Anti-Androgens: These drugs block the effects of androgens (male hormones) on cancer cells.
- Surgical Castration: This involves the surgical removal of the testes to reduce testosterone production.
- Chemotherapy: In some instances, chemotherapy may be recommended, either alone or in combination with hormonal therapy.
- Radiation Therapy: Radiation may be used in certain cases to target the prostate gland and surrounding tissues.
Hormone Sensitive Advanced Prostate Cancer Epidemiology
The Hormone Sensitive Advanced Prostate Cancer epidemiology section provides insights about the historical and current Hormone Sensitive Advanced Prostate Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Hormone Sensitive Advanced Prostate Cancer market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Hormone Sensitive Advanced Prostate Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Hormone Sensitive Advanced Prostate Cancer Epidemiology
The epidemiology segment also provides the Hormone Sensitive Advanced Prostate Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Get detailed insights into the historical as well as forecasted epidemiology trends in the 7MM, at: Prostate Cancer Epidemiology Forecast
Hormone Sensitive Advanced Prostate Cancer Recent Developments
- In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx® and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
- In September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
- In July 2024, the ARANOTE trial showed that NUBEQA® plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
- In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
- In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 with Abiraterone for mCRPC.
- In May 2024, Fusion Pharmaceuticals began the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.
- In April 2024, Astellas Pharma received European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
- In April 2024, FibroGen announced positive Phase 1 trial data for FG-3246 in mCRPC.
- On November 16, 2023, the FDA approved enzalutamide (Xtandi) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence.
- In August 2022, the FDA approved darolutamide in combination with docetaxel chemotherapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC). This is an additional treatment option for patients with mHSPC.
Hormone Sensitive Advanced Prostate Cancer Drug Chapters
The drug chapter segment of the Hormone Sensitive Advanced Prostate Cancer report encloses the detailed analysis of Hormone Sensitive Advanced Prostate Cancer marketed drugs and late-stage (Phase-III and Phase-II) Hormone Sensitive Advanced Prostate Cancer pipeline drugs. It also helps to understand the Hormone Sensitive Advanced Prostate Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Hormone Sensitive Advanced Prostate Cancer Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Hormone Sensitive Advanced Prostate Cancer treatment.
Hormone Sensitive Advanced Prostate Cancer Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Hormone Sensitive Advanced Prostate Cancer treatment.
Hormone Sensitive Advanced Prostate Cancer Market Outlook
The Hormone Sensitive Advanced Prostate Cancer market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hormone Sensitive Advanced Prostate Cancer market trends by analyzing the impact of current Hormone Sensitive Advanced Prostate Cancer therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Hormone Sensitive Advanced Prostate Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hormone Sensitive Advanced Prostate Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Hormone Sensitive Advanced Prostate Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Hormone Sensitive Advanced Prostate Cancer market in 7MM.
The United States Market Outlook
This section provides the total Hormone Sensitive Advanced Prostate Cancer market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Hormone Sensitive Advanced Prostate Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Hormone Sensitive Advanced Prostate Cancer market size and market size by therapies in Japan is also mentioned.
Hormone Sensitive Advanced Prostate Cancer Drugs Uptake
This section focuses on the rate of uptake of the potential Hormone Sensitive Advanced Prostate Cancer drugs recently launched in the Hormone Sensitive Advanced Prostate Cancer market or expected to get launched in the market during the study period 2019-2032. The analysis covers Hormone Sensitive Advanced Prostate Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Hormone Sensitive Advanced Prostate Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Hormone Sensitive Advanced Prostate Cancer market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hormone Sensitive Advanced Prostate Cancer Pipeline Development Activities
The Hormone Sensitive Advanced Prostate Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hormone Sensitive Advanced Prostate Cancer key players involved in developing targeted therapeutics.
Hormone Sensitive Advanced Prostate Cancer Pipeline Development Activities
The Hormone Sensitive Advanced Prostate Cancer report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Hormone Sensitive Advanced Prostate Cancer emerging therapies.
Reimbursement Scenario in Hormone Sensitive Advanced Prostate Cancer
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views on Hormone Sensitive Advanced Prostate Cancer Market Trends and Dynamics
To keep up with current Hormone Sensitive Advanced Prostate Cancer market trends, we take KOLs and SMEs ' opinion working in the Hormone Sensitive Advanced Prostate Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hormone Sensitive Advanced Prostate Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Hormone Sensitive Advanced Prostate Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Hormone Sensitive Advanced Prostate Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Hormone Sensitive Advanced Prostate Cancer epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Hormone Sensitive Advanced Prostate Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Hormone Sensitive Advanced Prostate Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hormone Sensitive Advanced Prostate Cancer market
Report Highlights
- In the coming years, the Hormone Sensitive Advanced Prostate Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Hormone Sensitive Advanced Prostate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Hormone Sensitive Advanced Prostate Cancer. The launch of emerging therapies will significantly impact the Hormone Sensitive Advanced Prostate Cancer market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hormone Sensitive Advanced Prostate Cancer
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Hormone Sensitive Advanced Prostate Cancer Report Insights
- Hormone Sensitive Advanced Prostate Cancer Patient Population
- Hormone Sensitive Advanced Prostate Cancer Therapeutic Approaches
- Hormone Sensitive Advanced Prostate Cancer Pipeline Analysis
- Hormone Sensitive Advanced Prostate Cancer Market Size and Trends
- Hormone Sensitive Advanced Prostate Cancer Market Opportunities
- Impact of upcoming Hormone Sensitive Advanced Prostate Cancer Therapies
Hormone Sensitive Advanced Prostate Cancer Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Hormone Sensitive Advanced Prostate Cancer Epidemiology Segmentation
- Key Cross Competition in the Hormone Sensitive Advanced Prostate Cancer Market
- Highly Analyzed Hormone Sensitive Advanced Prostate Cancer Market
- Hormone Sensitive Advanced Prostate Cancer Drugs Uptake
Hormone Sensitive Advanced Prostate Cancer Report Assessment
- Current Hormone Sensitive Advanced Prostate Cancer Treatment Practices
- Unmet Needs
- Hormone Sensitive Advanced Prostate Cancer Pipeline Product Profiles
- Hormone Sensitive Advanced Prostate Cancer Market Attractiveness
- Hormone Sensitive Advanced Prostate Cancer Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Hormone Sensitive Advanced Prostate Cancer drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Hormone Sensitive Advanced Prostate Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Hormone Sensitive Advanced Prostate Cancer market size during the forecast period (2019-2032)?
- At what CAGR, the Hormone Sensitive Advanced Prostate Cancer market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Hormone Sensitive Advanced Prostate Cancer market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Hormone Sensitive Advanced Prostate Cancer market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Hormone Sensitive Advanced Prostate Cancer?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Hormone Sensitive Advanced Prostate Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Hormone Sensitive Advanced Prostate Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hormone Sensitive Advanced Prostate Cancer?
- Out of all 7MM countries, which country would have the highest prevalent population of Hormone Sensitive Advanced Prostate Cancer during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Hormone Sensitive Advanced Prostate Cancer treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Hormone Sensitive Advanced Prostate Cancer in the USA, Europe, and Japan?
- What are the Hormone Sensitive Advanced Prostate Cancer marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Hormone Sensitive Advanced Prostate Cancer?
- How many therapies are in-development by each company for Hormone Sensitive Advanced Prostate Cancer treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Hormone Sensitive Advanced Prostate Cancer treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Hormone Sensitive Advanced Prostate Cancer therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hormone Sensitive Advanced Prostate Cancer and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Hormone Sensitive Advanced Prostate Cancer?
- What are the global historical and forecasted market of Hormone Sensitive Advanced Prostate Cancer?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Hormone Sensitive Advanced Prostate Cancer market
- To understand the future market competition in the Hormone Sensitive Advanced Prostate Cancer market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Hormone Sensitive Advanced Prostate Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Hormone Sensitive Advanced Prostate Cancer market
- To understand the future market competition in the Hormone Sensitive Advanced Prostate Cancer market
Stay Updated with us for Recent Articles- Latest DelveInsight Blogs
